Zhejiang Ausun Pharmaceutical Co., Ltd.SSE: 603229

Report for Q3 2024

Oct 30, 2024 · Issued by Zhejiang Ausun Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Oct 30, 2024

On 6ix: 6ix.com/news/report-for-q3-2024-252

Report for Q3 2024

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Zhejiang Ausun Pharmaceutical Co., Ltd. on 6ix

Earlier from Zhejiang Ausun Pharmaceutical

Announcement on Convening Semi-annual Performance Briefing 2024Aug 24, 2024

Later from Zhejiang Ausun Pharmaceutical

Announcement on Wholly-owned Subsidiary Obtaining "Drug Registration Certificate" for Sitafloxacin TabletsDec 6, 2024
Announcement on Returning the Raised Funds Used for Temporarily Supplementing the Working CapitalDec 13, 2024
Announcement onUsing Some Idle Raised Funds to Temporarily Supplement Current CapitalDec 14, 2024
Announcement on Obtaining Overseas Marketing Authorization for Cooperative Product Imatinib Mesylate TabletsDec 21, 2024
Indicative Announcement on the Proposal from Controlling Shareholder, Actual Controller, and Chairman & General Manager to Repurchase SharesJan 15, 2025

All Zhejiang Ausun Pharmaceutical news releases

Follow Zhejiang Ausun Pharmaceutical into a list and get an email when it puts out news.

Follow Zhejiang Ausun Pharmaceutical